EUVIMEDEUVIMED entdecken
Crossref

Phase III Probability of Success When Early Development Is Based on a Putative Surrogate Endpoint: A Vaccine Efficacy Case Study

Andrea Callegaro iD, Francesca Solmi, Silvia Noirjean, Valentino Conti, Fabian Tibaldi, Alessia Eletti iD

Pharmaceutical Statistics · 2026-05 · 25 (3)

DOI: 10.1002/pst.70095 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Statistics, online erschienen am 01.05.2026. Verfasst von Andrea Callegaro und 5 weiteren Autor:innen. Beteiligte Einrichtung: GSK Vaccines, Wavre, Belgium. Hauptthemen laut MEDLINE: Endpoint Determination, Clinical Trials, Phase III as Topic, Drug Development, Vaccine Efficacy. Die Arbeit nennt 20 Literaturangaben. Gefördert von: GlaxoSmithKline.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As Phase III trial costs and durations rise, pharmaceutical companies increasingly use quantitative methods to decide if a drug should progress beyond Phase II. A key method is the probability of success (PoS) for Phase III, calculated using the power function averaged across a treatment effect distribution estimated from Phase II. This paper explores PoS's role, particularly in moving from Phase II trials with putative surrogate endpoints to Phase III trials with clinical endpoints. Since the relationship between these endpoints is often unknown, expert input is necessary (prior elicitation). We propose the bivariate meta‐analysis and a copula‐based extension to characterize their relationship, using visual tools to simplify parameter elicitation. Specifically, we begin by eliciting the marginal distributions of the two quantities of interest. Then, to assist in eliciting the concordance parameter, we use the distribution of the treatment effect on the clinical endpoint conditional on the treatment effect on the putative surrogate. Our approach is illustrated in prophylactic vaccine development, linking immunological and clinical endpoints.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endpoint DeterminationClinical Trials, Phase III as TopicDrug DevelopmentVaccine EfficacyVaccinesHumansBiomarkersProbabilityMeta-Analysis as TopicBayes TheoremClinical Trials, Phase II as Topic

Stichwörter der Autor:innen

Bayesianassuranceexpert elicitationprior elicitationprobability of successsurrogate endpoint

Substanzen

BiomarkersVaccines

Autor:innen und Institutionen

  • GSK Vaccines, Wavre, Belgium.
  • GSK Vaccines, Siena, Italy.
  • GSK Vaccines Institute for Global Health, Siena, Italy.

ORCID-Profile: Andrea Callegaro, Alessia Eletti

Förderung

  • GlaxoSmithKline

Zitieren

APA

Callegaro, A., Solmi, F., Noirjean, S., Conti, V., Tibaldi, F., & Eletti, A. (2026). Phase III Probability of Success When Early Development Is Based on a Putative Surrogate Endpoint: A Vaccine Efficacy Case Study. Pharmaceutical Statistics, 25(3). https://doi.org/10.1002/pst.70095

Vancouver

Callegaro A, Solmi F, Noirjean S, Conti V, Tibaldi F, Eletti A. Phase III Probability of Success When Early Development Is Based on a Putative Surrogate Endpoint: A Vaccine Efficacy Case Study. Pharmaceutical Statistics. 2026;25(3). doi:10.1002/pst.70095

BibTeX
@article{Callegaro2026,
  author = {Callegaro, Andrea and Solmi, Francesca and Noirjean, Silvia and Conti, Valentino and Tibaldi, Fabian and Eletti, Alessia},
  title = {Phase III Probability of Success When Early Development Is Based on a Putative Surrogate Endpoint: A Vaccine Efficacy Case Study},
  journal = {Pharmaceutical Statistics},
  year = {2026},
  volume = {25},
  number = {3},
  doi = {10.1002/pst.70095}
}
Kostenlos starten →